

BELATACEPT

BRAND NAME	NULOJIX
DRUG CLASS	Immunosuppressant antibody
AVAILABILITY	Vial contains 250 mg of belatacept. Also contains sucrose, monobasic sodium phosphate and sodium chloride. Supplied with silicon-free syringe. ¹
pH	7.2–7.8 when reconstituted ¹
PREPARATION	Reconstitute the vial with 10.5 mL of water for injections, sodium chloride 0.9% or glucose 5% to make a concentration of 25 mg/mL. Only use the silicone-free syringe that is provided in the box. Rotate and gently invert the vial to avoid foaming. Do not shake. The solution is clear to slightly opalescent and colourless to pale yellow. ¹
STABILITY	Vial: store at 2 to 8 °C. Protect from light. ¹ Reconstituted solution: use immediately. ¹ Infusion solution: stable for 24 hours at 2 to 8 °C and 4 hours below 25 °C. ¹ Complete the infusion within 24 hours of preparation. ¹
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Not recommended
IV injection	Not recommended
IV infusion	Dilute the dose in 100 mL of compatible fluid. Only use the silicone-free syringe that is provided in the box. Total infusion volumes ranging from 50 mL to 250 mL may be used. Infuse over 30 minutes using a 0.2–1.2 micrometre low-protein-binding filter. ¹
COMPATIBILITY	
Fluids	Glucose 5% ¹ , sodium chloride 0.9% ¹
Y-site	No information
INCOMPATIBILITY	No information
SPECIAL NOTES	If a syringe containing silicone is accidentally used the solution may develop a few translucent particles and must be discarded. ¹

REFERENCES

1. Nulojix. Product information. Noble Park, Vic.: Bristol-Myers-Squibb. Approved 27/02/12. Available from www.tga.gov.au/pdf/auspar/auspar-belatacept-120730.pdf. Accessed 19/05/16.